Eliminate the uncertainty of your future
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
BRCANOW is a next-generation sequencing panel for people with a personal or family history of breast or ovarian cancer.
For hereditary screening, we offer two versions of the BRCANOW test, BRCANOW Basic and BRCANOW Extended, with reflex options available. In addition to BRCA1 & BRCA2, which account for most hereditary breast and ovarian cancers, the BRCANOW Extended panel includes additional genes that are less common but known to be associated with hereditary breast and ovarian cancers. Both versions of the assay utilize next-generation sequencing to detect single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes, providing >20X average coverage at the targeted genomic regions of the tested genes.
BRCANow® Extended Panel 30 analyzed genes
Risk of cancer in individuals with a BRCA1
or BRCA2 mutation
or BRCA2 mutation
- 80%Breast mutation BRCA1
- 40%Ovarian mutation BRCA1
- 30%Prostate mutation BRCA1
- 3%Pancreatic mutation BRCA1
- 70%Breast mutation BRCA2
- 18%Ovarian mutation BRCA2
- 39%Prostate mutation BRCA2
- 7%Pancreatic mutation BRCA2
This GENETICSNOW Comprehensive analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
PROSTATENOW is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
LYNCHNOW is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.
DIABETESNOW is a unique genetic panel that tests for 16 genes associated with MODY, syndromic, neonatal, and mitochondrial causes of monogenic diabetes. It also includes pan-ancestry type 1 and 2 diabetes polygenic risk scores (PRS) and the probability of type 1 diabetes (GenProb-T1D).
GeneticsNow Navigation Team
Providing “white glove” support to patients and providers
- Personalized Support: Tailored assistance to meet each patient’s unique needs, ensuring everyone receives the care and guidance they deserve.
- Education & Counseling: Genetic counseling before and after testing to help patients and families understand risks, limitations, and results.
- Financial Assistance: Support for uninsured or low-income patients to make testing accessible and affordable.
- Care Coordination: Collaboration with medical teams to simplify authorizations and appeals, reducing the administrative burden on providers.
- Ongoing Support: Cascade testing and continued guidance for families with a confirmed genetic mutation.
